Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 24, 2009Antimicrobial Agents and ChemotherapyOpen Access

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

View Full Paper
Ask AI
Bookmark
Share

Authors

HAHilde AzijnUniversity of Massachusetts Chan Medical SchoolITIlse TirryJVJohan VingerhoetsJohnson & Johnson (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Azijn et al. (2009) studied this question.

synapsesocial.com/papers/6a819eaeffaafd634258bef6https://doi.org/10.1128/aac.00986-09
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 12004 · 323 citations
  2. 2Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor2004 · 243 citations
  3. 3Cross-Resistance among Nonnucleoside Reverse Transcriptase Inhibitors Limits Recycling Efavirenz after Nevirapine Failure2002 · 134 citations
  4. 4A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding2003 · 361 citations